PFE vs REPL

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...

Replimune (REPL) maintains a high-conviction, high-risk, high-reward profile, with its score slightly increasing due to recent positive developments. The previous analysis heavily anticipated pivotal RP1 data, and an update from the Phase 3 IGNYTE trial in anti-PD1 failed melanoma patients showing a 32% ORR (Mar 22, 2026) provides strong preliminary validation. This significantly de-risks the prim...